World Atopic Dermatitis Pipeline Review, H2 2017 - Research and Markets

DUBLIN--()--The "Atopic Dermatitis - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Atopic Dermatitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 5, 40, 20, 1, 47, 15 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 3 and 2 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Atopic Dermatitis - Overview
  3. Atopic Dermatitis - Therapeutics Development
  4. Atopic Dermatitis - Therapeutics Assessment
  5. Atopic Dermatitis - Companies Involved in Therapeutics Development
  6. Atopic Dermatitis - Drug Profiles
  7. Atopic Dermatitis - Dormant Projects
  8. Atopic Dermatitis - Discontinued Products
  9. Atopic Dermatitis - Product Development Milestones
  10. Appendix

Companies Mentioned

  • AbbVie Inc
  • Abeome Corp
  • Accolade Pharmaceuticals LLC
  • Albireo Pharma Inc
  • Allergan Plc
  • Almirall SA
  • Amgen Inc
  • Asana BioSciences LLC
  • Aslan Pharmaceuticals Pte Ltd
  • Bioleaders Corp
  • Blueberry Therapeutics Ltd
  • Brickell Biotech Inc
  • Celgene Corp
  • Eli Lilly and Company
  • Exicure Inc
  • F. Hoffmann-La Roche Ltd
  • Foamix Pharmaceuticals Ltd
  • Fountain Biopharma Inc
  • Galapagos NV
  • Galectin Therapeutics Inc
  • GlaxoSmithKline Plc
  • LEO Pharma A/S
  • Madam Therapeutics BV
  • MedImmune LLC
  • NeoPharm Co Ltd
  • Novan Inc
  • Novartis AG
  • Orbis Biosciences Inc
  • Otsuka Holdings Co Ltd
  • Oxagen Ltd
  • Pfizer Inc
  • Valeant Pharmaceuticals International Inc
  • VivaCell Biotechnology Espana SL
  • Xencor Inc
  • Zhejiang I-Biological Technology Co Ltd

For more information about this report visit https://www.researchandmarkets.com/research/trhktj/atopic_dermatitis

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Dermatological Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Dermatological Drugs